The Latest Cardiac and Vascular News
Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients […]
Patent provides intellectual property protection until December 2040 PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 There are currently no FDA approved treatments for PH-HFpEF Levosimendan combines two MoAs that, for the first time, specifically target the symptoms PH-HFpEF patients […]
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it will be executing a reverse stock split of its outstanding shares […]
MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with […]
MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January […]
Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Transition Substudy for TNX-103 (oral levosimendan) Plans to Initiate Phase 3 Study of TNX-201 (oral imatinib mesylate) in Pulmonary Arterial Hypertension in 2H 2022 Forms Scientific Advisory Board with Expertise in Pulmonary […]
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the third quarter of 2021 and provided a business update. “As we approach the new year, […]
Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary […]
Levosimendan was shown to Reduce Stressed Blood Volume (SBV), a Novel and Highly Relevant Mechanism of Action for PH-HFpEF Patients Stressed Blood Volume Reductions Accompany Previously Reported Improvements in Important Cardiovascular Hemodynamic Measurements Reduction in Stressed Blood Volume Suggests the Effects of Levosimendan are Modulated Through K-ATP Channel Activation and […]
– Anthony DiTonno Retires from Tenax; Christopher Giordano Appointed as CEO – MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company that address cardiovascular and pulmonary diseases with high unmet medical need, today announced a CEO transition in connection with the retirement of its current CEO: Effective July 13, […]
